Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Lidocaine + phenazone** is a combination otic solution used for symptomatic relief of pain and inflammation in acute otitis media and other ear conditions with intact tympanic membrane. Lidocaine, a local anesthetic of the amide class, blocks sodium channels in neuronal membranes to inhibit nerve signal transmission and numb pain. Phenazone, a pyrazolone derivative and non-steroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis to reduce inflammation, fever, and pain, while also potentiating lidocaine's anesthetic effect through enhanced local bioavailability. Primarily administered as ear drops for otitis media (congestive phase), viral otitis, and barotrauma in children over 6 months and adults; contraindicated in tympanic perforation.[1][2][3][4][9]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lidocaine + phenazone.